Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii

被引:11
|
作者
Kon, Hadas [1 ]
Hameir, Amichay [1 ]
Nutman, Amir [1 ,2 ]
Temkin, Elizabeth [1 ]
Keren Paz, Alona [1 ]
Lellouche, Jonathan [1 ,3 ]
Schwartz, David [1 ]
Weiss, David S. [4 ]
Kaye, Keith S. [5 ]
Daikos, George L. [6 ,7 ]
Skiada, Anna [6 ,7 ]
Durante-Mangoni, Emanuele [8 ,9 ]
Dishon Benattar, Yael [10 ,11 ]
Yahav, Dafna [2 ,12 ]
Daitch, Vered [2 ,13 ]
Bernardo, Mariano [14 ]
Iossa, Domenico [8 ]
Friberg, Lena E. [15 ]
Theuretzbacher, Ursula [16 ]
Leibovici, Leonard [2 ,13 ]
Dickstein, Yaakov [10 ]
Pollak, Dina [17 ]
Mendelsohn, Sigal [17 ]
Paul, Mical [10 ]
Carmeli, Yehuda [1 ,2 ]
AIDA Study Grp
机构
[1] Israel Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[3] Ariel Univ, Adelson Sch Med, Ariel, Israel
[4] Emory Univ, Emory Antibiot Resistance Ctr, Sch Med, Atlanta, GA USA
[5] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ USA
[6] Laikon Gen Hosp, Dept Med 1, Athens, Greece
[7] Natl & Kapodistrian Univ Athens, Athens, Greece
[8] Univ Campania Luigi Vanvitelli, Dept Precis Med, Naples, Italy
[9] AORN Colli Monaldi Hosp, Naples, Italy
[10] Inst Infect Dis, Rambam Hlth Care Campus, Haifa, Israel
[11] Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Techn, Haifa, Israel
[12] Beilinson Med Ctr, Rabin Med Ctr, Infect Dis Unit, Petah Tiqwa, Israel
[13] Beilinson Med Ctr, Rabin Med Ctr, Dept Med E, Petah Tiqwa, Israel
[14] AORN Ospedali Colli Monaldi Hosp, Microbiol & Virol Unit, Naples, Italy
[15] Uppsala Univ, Dept Pharm, Uppsala, Sweden
[16] Ctr Antiinfect Agents, Vienna, Austria
[17] Microbiol Lab, Rambam Hlth Care Campus, Haifa, Israel
关键词
Acinetobacter baumannii; carbapenem-resistance; colistin; heteroresistance; population analysis profiling; ASSOCIATION; BLOOD;
D O I
10.1128/spectrum.05093-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Colistin heteroresistance (HR) refers to a bacterial population comprised of several subpopulations with different levels of resistance to colistin. In this study, we discuss the classic form of HR, in which a resistant subpopulation exists within a predominantly susceptible population. We investigated the prevalence of colistin HR and its evolution into full resistance among 173 clinical carbapenem-resistant Acinetobacter baumannii isolates and examined the effect of HR on clinical outcomes. To determine HR, we performed population analysis profiling. Our results showed a high prevalence of HR (67.1%). To examine evolution of HR strains into full resistance, the HR strains were grown in colistin-containing broth, transferred onto colistin-containing plates, and colonies on these plates were transferred into colistin-free broth. Many of the HR strains (80.2%) evolved into full resistance, 17.2% reverted to HR, and 2.6% were borderline. We used logistic regression to compare 14-day clinical failure and 14-day mortality between patients infected by HR versus susceptible non-HR carbapenem-resistant A. baumannii. In the subgroup of patients with bacteremia, HR was significantly associated with 14-day mortality.IMPORTANCE To our knowledge, this is the first large-scale study to report on HR in Gram-negative bacteria. We described the prevalence of colistin HR in a large sample of carbapenem-resistant A. baumannii isolates, the evolution of many colistin HR isolates to a resistant phenotype following colistin exposure and withdrawal, and the clinical consequences of colistin HR. We found a high prevalence of HR among clinical carbapenem-resistant A. baumannii isolates; most evolved into a resistant phenotype following colistin exposure and withdrawal. In patients treated with colistin, evolution of HR A. baumannii into full resistance could lead to higher rates of treatment failure and contribute to the reservoir of colistin-resistant pathogens in health care settings. To our knowledge, this is the first large-scale study to report on HR in Gram-negative bacteria. We described the prevalence of colistin HR in a large sample of carbapenem-resistant A. baumannii isolates, the evolution of many colistin HR isolates to a resistant phenotype following colistin exposure and withdrawal, and the clinical consequences of colistin HR.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Effect of colistin-tigecycline combination on colistin-resistant and carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii
    Park, Suyeon
    Jin, Yanhong
    Ko, Kwan Soo
    MICROBIOLOGY SPECTRUM, 2025, 13 (02)
  • [22] Prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa and association with clinical outcomes in patients: an observational study
    Howard-Anderson, Jessica
    Davis, Michelle
    Page, Alexander M.
    Bower, Chris W.
    Smith, Gillian
    Jacob, Jesse T.
    Andersson, Dan, I
    Weiss, David S.
    Satola, Sarah W.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (03) : 793 - 798
  • [23] Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections:: clinical outcome and adverse events
    Petrosillo, N
    Chinello, P
    Proietti, MF
    Cecchini, L
    Masala, M
    Franchi, C
    Venditti, M
    Esposito, S
    Nicastri, E
    CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (08) : 682 - 683
  • [24] In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii
    Song, Joon Young
    Kee, Sae Yoon
    Hwang, In Sook
    Bin Seo, Yu
    Jeong, Hye Won
    Kim, Woo Joo
    Cheong, Hee Jin
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (02) : 317 - 322
  • [25] Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates
    Vourli, Sophia
    Dafopoulou, Konstantina
    Vrioni, Georgia
    Tsakris, Athanassios
    Pournaras, Spyros
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (09) : 2528 - 2530
  • [26] Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections
    Shields, Ryan K.
    Dorazio, Ava J.
    Tiseo, Giusy
    Squires, Kevin M.
    Leonildi, Alessandro
    Giordano, Cesira
    Kline, Ellen G.
    Barnini, Simona
    Iovleva, Alina
    Griffith, Marissa P.
    Van Tyne, Daria
    Doi, Yohei
    Falcone, Marco
    JAC-ANTIMICROBIAL RESISTANCE, 2024, 6 (05):
  • [27] Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland
    A. Ramette
    A. Kronenberg
    BMC Infectious Diseases, 18
  • [28] Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
    Sirijatuphat, Rujipas
    Thamlikitkul, Visanu
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (09) : 5598 - 5601
  • [29] Adaptive resistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii (CRAB): microbiological and clinical issues
    Desmoulin, Anissa
    Sababadichetty, Loik
    Kamus, Laure
    Daniel, Marion
    Feletti, Lucie
    Allou, Nicolas
    Potron, Anals
    Leroy, Anne-Gaelle
    Jaffar-Bandjee, Marie -Christine
    Belmonte, Olivier
    Garrigos, Thomas
    Miltgen, Guillaume
    HELIYON, 2024, 10 (09)
  • [30] Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland
    Ramette, A.
    Kronenberg, A.
    BMC INFECTIOUS DISEASES, 2018, 18